A carregar...
CIP2A is a target of bortezomib in human triple negative breast cancer cells
INTRODUCTION: Triple negative breast cancer (TNBC) is very aggressive and currently has no specific therapeutic targets, such as hormone receptors or human epidermal growth factor receptor type 2 (HER2); therefore, prognosis is poor. Bortezomib, a proteasome inhibitor, may exert efficacy in TNBC thr...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3446403/ https://ncbi.nlm.nih.gov/pubmed/22537901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3175 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|